DISPERSE2-TIMI 33

DISPERSE2-TIMI 33 evaluated the safety, tolerability, and efficacy of AZD6140 (ticagrelor), an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome.

MAIN RESULTS:
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial

J Am Coll Cardiol. 2007 Nov 6;50(19):1844-51.

PRESENTATIONS

TIMI 33 Slides

OTHER PUBLICATIONS

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6.

Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am J Cardiol. 2009 Feb 1;103(3):307-11.

Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract. 2009 Apr;63(4):667-70.

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009 Aug;20(5):341-8.

Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol. 2010 Apr;33(4):206-12.

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. Am Heart J. 2018 Aug;202:54-60.